1 Day
Source:
اقتصاد سكاي نيوز عربية
Novo Nordisk: UAE as a hub for innovative medicines
Novo Nordisk has announced its entry into the United Arab Emirates market with the drug "Wegovy" in the form of oral tablets for the treatment of obesity. The company considers the UAE a natural choice for expanding into the most innovative pharmaceutical markets, with a focus on innovation and enabling patient access across different markets. To achieve this, the company successfully transformed "Wegovy" from an injection into an oral tablet, enhancing safety and convenience while reducing the barrier of needle phobia or cultural reservations towards injections. The drug is unique due to data confirming its efficacy and safety, as well as its benefits for the heart, kidneys, and liver, thereby broadening its use to include patients with various conditions related to obesity and related diseases.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)